Geode Capital Management LLC Has $779,000 Stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX)

Geode Capital Management LLC grew its holdings in Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) by 937.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 104,853 shares of the company's stock after purchasing an additional 94,742 shares during the period. Geode Capital Management LLC owned about 1.01% of Avalo Therapeutics worth $779,000 at the end of the most recent quarter.

Analyst Upgrades and Downgrades

Several research firms have weighed in on AVTX. Jefferies Financial Group began coverage on Avalo Therapeutics in a research report on Tuesday, March 25th. They set a "buy" rating and a $23.00 price target on the stock. HC Wainwright reiterated a "neutral" rating on shares of Avalo Therapeutics in a research note on Thursday, March 20th. Wedbush reaffirmed an "outperform" rating and issued a $18.00 target price on shares of Avalo Therapeutics in a report on Thursday, March 20th. Stifel Nicolaus began coverage on Avalo Therapeutics in a research report on Tuesday, March 25th. They set a "buy" rating and a $36.00 price target on the stock. Finally, Piper Sandler assumed coverage on Avalo Therapeutics in a research report on Friday, February 28th. They issued an "overweight" rating and a $48.00 price objective for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $33.00.

Avalo Therapeutics Price Performance

Shares of NASDAQ AVTX traded down $0.33 during trading hours on Wednesday, reaching $4.45. 193,145 shares of the stock were exchanged, compared to its average volume of 53,459. Avalo Therapeutics, Inc. has a 52 week low of $4.15 and a 52 week high of $16.00. The stock's fifty day simple moving average is $6.24 and its 200 day simple moving average is $8.26.

Avalo Therapeutics Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.